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Influence of Early Prehospital Thrombolysis on Mortality and Event-
The Myocardial Infarction Triage and Intervention Trial of prehospital versus hospital administration of throm bolytic therapy markedly reduced hospital treatment times, but the 2 groups had similar outcomes* However, patients treated < 7 0 minutes from symptom onset had better short-term outcomes. The purpose of this study was to determine the long-term influence of very early thrombolytic treatment for acute myocardial infarction. A total of 360 patients were followed for vital status and cardiac-related hospital admissions over a period of 34 ± 1 6 months. Patients enrolled in the trial had symptoms for ^6 hours, ST-segment elevation on the prehospital electrocardiogram, and no risk factors for serious bleed ing, They received aspirin and recombinant tissue plas minogen activator either before or after hospital arrival. Primary end points in this study included long-term sur vival and survival free of death or readmission to the hospital for angina, myocardial infarction, congestive heart failure, or revascularization. Two-year survival was 89% for prehospital-and 91% for hospital-treated patients (p = 0.46), Event-free survival at 2 years w as 56% and 64% for prehospital-and hospitahtreated pa tients, respectively (p = 0.42). In patients treated < 7 0 minutes from symptom onset, 2-year survival w as 98%, and it was 88% for those treated later (p = 0.12). Twoyear event-free survival w as 65% for patients treated early and 59% for patients treated later (p = 0.80). In this trial, poorer long-term survival w as associated with advanced age, history of congestive heart failure, and coronary artery bypass surgery performed before the index hospitalization, but not with time to treatment. (Am i Cardiol 1996;78:497-502) thrombolytic therapy has been proven to reduce early mortality and to im prove 1-year survival rates in patients w ith acute m yocardial infarction,1"7 T he greatest m ortality reduction is show n in patients w ho receive treatm ent w ithin the first 1 to 2 hours after sym ptom onset. 3, 5, 6, 8 In several studies that have determ ined the com ponents o f treatm ent delay, pa tient decision tim e and hospital treatm ent times each could account for ^1 h o u r.14" 11 Prehospital initiation of throm bolytic therapy m ight therefore provide the opportunity to treat a large proportion of patients within the first 2 hours o f sym ptom onset. Tw o trials of prehospital throm bolytic therapy dem onstrated significant reductions in tim e to treatm ent, although mortality in the preho spi ta I_ and hospital groups was In the M yocardial In- 12.13 farction Triage and Intervention (MITI) prehospital trial, time to treatm ent was reduced by 33 minutes in the prehospital group. In addition, patients treated < 7 0 minutes from sym ptom onset had lower mor tality, sm aller infarct size, and im proved left ventric ular function.13 O ver the years, several studies re porting the long-term influence of thrombolytic therapy have been published.14" ,6
The purpose of the current study was to determ ine w hether the benefits of very early treatm ent w ere sustained in the years after discharge from the hospital.
METHODS

Patient population:
All patients who called 91 1 and had chest pain w ere evaluated by the 15 paramedic units in the Seattle metropolitan area. Using a checklist with inclusion and exclusion criteria, par amedics gathered inform ation on the patients1 clini cal presentations. This inform ation enabled hospitalbased physicians to determ ine w hether the patients were candidates for throm bolytic therapy. Patients w ere excluded from participating in the trial for the following reasons: ( I ) chest pain > 6 hours from sym ptom onset, (2 ) age > 7 5 years, or (3 ) the pres ence of com plicating illnesses that were considered to be contraindications for prehospital thrombolytic therapy. D etailed inform ation on the study protocol and criteria for patient selection have been pub lish ed .11,1B riefly, a 12-lead prehospital electrocardiogram was obtained in the subset o f patients who satisfied the criteria for enrollm ent. T he final decision to ran dom ize the patient was m ade by a physician in the em ergency departm ent o f I o f 6 param edic base hos pitals. P aram edics used a standard verbal consent to enroll patients into the study. A fter enrollm ent, pa tients w ere random ized to receive aspirin and recom binant tissue plasm inogen activator either before or after hospital arrival. Intravenous sodium heparin w as adm inistered to both patient groups at the time of hospital arrival. After hospital discharge, 289 pa** dents underw ent radionuclide measurements of in farct size and left ventricular ejection fraction. The prim ary end points of this study were survival and event-free survival, defined as survival free of death, m yocardial infarction, or hospitalization for angina, congestive heart failure, or revascularization. Survival analyses included deaths from all causes. Survival curves fo ra li groups were obtained according to the m ethod o f Kaplan and M eier, 17 The log rank test w as used to determ ine whether survival and event-free survival were dif ferent according to random ization group and time to continuous varu 'S,
RESULTS
Of all 360 patients, 175 w ere random ized to re ceive prehospital-initiated throm bolytic therapy, and the other 185 w ere allocated to throm bolytic treat m ent after hospital arrival. B aseline characteristics o f these patients have been described.'-1 C ardiac his tories and hem odynam ic findings did not differ sig nificantly betw een the groups, and baseline electro cardiographic findings were also similar: Anterior infarction occurred in 39% (p = 0.99) and inferior infarction in 58% (p = 0.99) o f both groups. Patients in the hospital group w ere slightly older than their counterparts (59 ± 10 years in the prehospital group vs 57 ± 10 years in the hospital group; p = 0.04). T im e from sym ptom onset to treatm ent differed sig nificantly; the m edian time to treatm ent for the pre hospital group was 77 minutes (56 and 101; 25th and 75th percentiles), and it w as 110 m inutes (85 O verall, 336 patients received thrombolytic ther apy in either the prehospital or the hospital setting; 24 did not receive throm bolytic treatment for varying reaso n s.13 In nearly 25% (82 of 336) of the patients receiving throm bolytic therapy, tim e from symptom onset to treatm ent was < 7 0 minutes, M ost were treated later; 254 patients received thrômbolytic therapy betw een 70 minutes and 3 hours o f symptom onset.
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T he baseline characteristics o f patients treated early ( < 7 0 m inutes) and of those treated later were sim ilar. Patients in the early group were slightly younger, although this difference was not statisti cally significant (56 ± 10 years in the early-treated patients vs 58 ± 10 years in the later-treated patients; p -0.051 ). T im e to treatm ent showed a distinct dif ference: T he median time to treatment was 55 m inutes (4 9 and 63; 25th and 75th percentiles) for the early-treated patients com pared with 104.5 m inutes (85 and 141; 25th and 75th percentiles) for those w ho w ere treated later.
In the first year of follow-up, 31 patients died; inform ation on cardiac-related events was available for 97% o f patients. W ith the National Death Index and returned follow -up letters, it was possible to as certain vital status for all patients. Figure 1 shows cum ulative survival curves for the prehospital and hospital groups. There was no significant difference in long-term survival between the groups; 2-year sur vival w as 89% for prehospital-treated patients and 91% fo r those treated in the hospital setting (p = 0 .4 6 ). E vent-free survival also did not differ accord ing to random ization group (Figure 2 ) . Two years after enrollment, event-free survival was 56% and 64% in the prehospital and hospital groups, respec tively (p = 0.42).
To determ ine w hether patients differed in the num ber of cardiac-related events, we calculated event rates for both groups (T able I). The prehos pital group show ed a slightly low er number of car diac-related adm issions (p = 0 .2 8 ). Overall, there was a difference of 68 cardiac-related events per 1,000 patients per year (T able I). Hospital read mission rates at 1 and 2 years of follow-up were also determ ined. For the prehospital group, 31% and 36% of patients were rehospitalized at 1 and 2 years, respectively. In the hospital group, 25% of patients were readm itted at 1 year and 31% at 2 years (p = 0 . 6 5 ) .
During the first year of follow-up, 28 of 336 pa tients who received throm bolytic therapy died, In formation on cardiac-related events was available for 96% of surviving patients. Figure 3 shows the long term survival for the group that was treated very early versus the group that received thrombolytic agents ^7 0 minutes from sym ptom onset. Unad justed survival in the early-treatm ent group appeared to be improved, but the difference was not statisti cally significant, because the survival curves crossed after 3 years. Tw o-year survival was 98% for the early-treated patients and 88% for those who re ceived thrombolytics later (p = 0.1 2 ). Figure 4 shows that there was no significant dif ference in event-free survival between the very early and the later-treated group. Event-free survival at 2 years was 65% for the early group and 59% for the to treatm ent o f only 33 minutes, in stead o f the expected tim e of ^ I hour.13 This, com bined with the conservative selection criteria, and later group (p = 0.80). Event rates were sim ilar in the 2 groups (Table II) . Readm ission rates at 1 and 2 years of follow-up were 30% and 33% , respec tively, for the early-treated patients and 27% and 33% for those treated later. These differences were not statistically significant (p = 0.74).
To identify factors that were related to long-term survival, w e perform ed stepwise Cox m ultivariate regression analysis in 329 patients with com plete in formation. A dvanced age, a history o f heart failure, and bypass surgery perform ed before the index hos pitalization were associated with decreased survival. After adjustm ent for these variables, treatm ent < 7 0 m inutes from sym ptom onset was not associated with survival (p = 0.30). In addition, tim e to treat ment m easured as a continuous variable w as not pre dictive of long-term survival (p = 0 .8 4 ).
DISCUSSION
T im e to treatment is an im portant predictor of 11 « a hospital m ortality.3,8,1, The earlier throm bolytic treat ment is initiated, the more m yocardium is saved and the better the clinical outcome, A ccording to this hy pothesis, outcom e would be best in patients treated very early. W e conducted this follow -up study to assess the long-term influence of very early initiation of throm bolytic therapy.
T here was a trend toward im proved long-term survival after very early thrombolysis. T his benefit resulted primarily from a m uch more favorable inhospital mortality rate for patients treated very early. M oreover, readm ission rates and event-free survival were not influenced by a substantial reduction in time to treatment. Therefore, despite the m ajor im pact o f early treatment on short-term m ortality, the influence on long-term clinical outcom e was less im pressive. The benefits of very early treatm ent are im mediate; with the passage o f time, other factors, in cluding age and gender, as well as the use o f aspirin, ß blockers, risk factor reduction, or revascularization procedures, becom e preem inent for all patients.
Survival curves for the prehospital-and hospitaltreated patients were similar. These findings may have been influenced by the unanticipated reduction of 40 minutes in hospital treatment tim es in this study.13 Consequently, prehospital initiation of thrombolytic therapy resulted in a reduction in time the relatively low patient numbers, might have prevented the difference between treatm ent groups that was expected.
In the analysis o f early treatment, the earlier reported 30-day survival benefit for patients treated < 7 0 minutes from sym ptom onset re sulted in m arkedly im proved sur vival in this group. This gain was caused prim arily by a low er num ber of in-hospital deaths for the early-treated patients. Considering the entire follow -up period, the ob served difference betw een curves was not statisti cally significant (p = 0,12). In addition, results from Cox regression analysis indicated that early treat m ent was not associated with long-term survival/ These findings do not suggest that very early treat m ent exerts an additional salutary effect that was re alized in the first m onth after treatment.
Event-free survival was not influenced by a re duction in tim e to treatment. R eadm ission rates and event rates also did not differ significantly, The slightly higher event-free percentages in the very early-treated group w ere caused by the few er deaths in this group and not by a difference in hospital ad missions for cardiac events. T hese findings do not support the hypothesis that early treatm ent w ould re sult in improved overall cardiac status and thus few er subsequent admissions. A D utch study has suggested that freedom from reocclusion does result in im proved long-term event-free survival. 18 Follow-up in the M ITI prehospital throm bolysis trial demonstrated that short-and long-term clinical outcomes were sim ilar for prehospital-and hospitaltreated patients. Thirty-day survival was improved with very early throm bolytic therapy, but very early treatment did not decrease either subsequent survival or the num ber of cardiac events after hospital dis charge.
